Catherine Ansquer
Overview
Explore the profile of Catherine Ansquer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frey S, Bannani S, Caillard C, Le Bras M, Drui D, Ansquer C, et al.
Surgery
. 2024 Oct;
177:108878.
PMID: 39443204
Background: Multiglandular parathyroid disease, which is particularly frequent in patients with mild primary hyperparathyroidism, is a surgical challenge requiring bilateral cervicotomy with 4-gland exploration. Near-infrared autofluorescence of the parathyroid is...
2.
Lugat A, Chouin N, Chocteau F, Esnault M, Marionneau-Lambot S, Gouard S, et al.
Eur J Nucl Med Mol Imaging
. 2024 Sep;
52(2):730-743.
PMID: 39269657
Methods: A mouse model of liver metastases of pancreatic NETs was developed by intraportal injection of AR42J cells and explored using [ Ga]Ga-DOTATOC and [F]F-FDG PET/MRI. Biodistribution study and radiation...
3.
Schurrle S, Eberlein U, Ansquer C, Beauregard J, Durand-Gasselin L, Gronbaek H, et al.
Eur J Nucl Med Mol Imaging
. 2024 Mar;
51(8):2428-2441.
PMID: 38528164
Purpose: To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [Lu]Lu-satoreotide tetraxetan in patients with advanced neuroendocrine tumours (NETs). Methods: This study was part of a...
4.
Boucher A, Delabie J, Lussey-Lepoutre C, Haissaguerre M, Ouvrard E, Lavinia V, et al.
Eur J Nucl Med Mol Imaging
. 2023 Dec;
51(5):1349-1360.
PMID: 38057652
Purpose: The aims of the study were to evaluate the performance and robustness of [F]fluorocholine PET/CT in detecting hyperfunctioning parathyroid glands in MEN1-related primary hyperparathyroidism (pHPT) at different stages of...
5.
Wild D, Gronbaek H, Navalkissoor S, Haug A, Nicolas G, Pais B, et al.
Eur J Nucl Med Mol Imaging
. 2023 Sep;
51(1):183-195.
PMID: 37721581
Purpose: We present the results of an open-label, phase I/II study evaluating the safety and efficacy of the novel somatostatin receptor (SSTR) antagonist [Lu]Lu-satoreotide tetraxetan in 40 patients with previously...
6.
Lugat A, Frampas E, Touchefeu Y, Mirallie E, Le Bras M, Senellart H, et al.
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672462
The aim of this multicentric study was to prospectively compare 68Ga-DOTANOC PET/CT versus somatostatin receptor scintigraphy (SRS) with SPECT/CT, combined with multiphasic CT scan and MRI in patients with grade...
7.
Thuillier P, Ansquer C, Borson-Chazot F, Lussey-Lepoutre C
Ann Endocrinol (Paris)
. 2023 Jan;
84(2):327-328.
PMID: 36669736
No abstract available.
8.
Thuillier P, Benisvy D, Ansquer C, Corvilain B, Mirallie E, Taieb D, et al.
Ann Endocrinol (Paris)
. 2022 Oct;
83(6):401-406.
PMID: 36273578
The SFE-AFCE-SFMN 2022 consensus deals with the management of thyroid nodules, a condition that is a frequent reason for consultation in endocrinology. In more than 90% of cases, patients are...
9.
Lugat A, Drui D, Bach-Ngohou K, Guillot P, Mourrain-Langlois E, Kraeber-Bodere F, et al.
Clin Nucl Med
. 2022 Jan;
47(2):e197-e198.
PMID: 35006119
A 61-year-old woman presenting with hyperthyroidism received 131I therapy for a toxic adenoma diagnosed by 123I scintigraphy. Six months later, the patient had a relapse of hyperthyroidism, and 123I scintigraphy...
10.
Mennetrey C, Le Bras M, Bando-Delaunay A, Al-Mansour L, Haissaguerre M, Batisse-Lignier M, et al.
J Clin Endocrinol Metab
. 2021 Dec;
107(5):e2056-e2064.
PMID: 34940846
Context: Despite the growing evidence of the clinical value of somatostatin receptor (SSTR) positron emission tomography (PET) in the evaluation of neuroendocrine tumors (NETs), its role remains to be clarified...